Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

Medically reviewed by Casey Gallagher, MD Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

Sonelokimab has also been assessed in a randomized, placebo-controlled third party Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis. High threshold clinical ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

Top line results for the Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies 2 in moderate to severe plaque psoriasis, are expected in Q4 2024. Top line results for the Phase 2b ANTHEM multicenter, ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Stationary plaque psoriasis, which is usually a chronic ... The clinical severity of psoriasis Psoriasis is classified as mild, moderate, or severe. This classification takes account of the ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...

which is heading for an FDA decision next September in moderate to severe plaque psoriasis. That's important because deucravacitinib – aiming to become the first tyrosine kinase 2 (TYK2 ...

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions ...

our pivotal Phase 3 trial of ZORYVE foam in scalp and body plaque psoriasis. We enrolled patients with at least moderate ...